News & Updates
Filter by Specialty:

Are SGLT2 inhibitors cardioprotective in wild-type ATTR-CM patients?
The use of sodium glucose cotransporter-2 (SGLT2) inhibitors nearly halves the risk of all-cause mortality at 3 years in patients with wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) and type 2 diabetes (T2D), findings from an observational study suggest.
Are SGLT2 inhibitors cardioprotective in wild-type ATTR-CM patients?
05 Nov 2024
Data support abrocitinib use beyond 2 years in adolescents with AD
Treating adolescents with moderate-to-severe AD with the JAK1-selective inhibitor abrocitinib has demonstrated an acceptable long-term safety profile and maintained efficacy for up to 112 weeks, as shown in an adolescent-focused post hoc analysis of 5 phase III trials
Data support abrocitinib use beyond 2 years in adolescents with AD
05 Nov 2024
Opioid does little to ease pain in aSAH-related headache
Use of opioids results in small reductions in pain among adult patients with an aneurysmal subarachnoid haemorrhage (aSAH)-related headache, and higher doses do not appear to significantly boost its efficacy in relieving pain, according to a study.